타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 3개 · 임상 갱신 필요 3개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |||
|---|---|---|---|
Overview Program | Bimzelx (bimekizumab) | Cosentyx (secukinumab) | Ixekizumab |
Overview Company | UCB | Novartis | Eli Lilly and Company |
Overview Modality | ANTIBODY | ANTIBODY | ANTIBODY |
Overview Target | IL-17A / IL-17F | IL-17A | Psoriatic Arthritis |
Overview Indication | Plaque psoriasis, psoriatic arthritis, axial spondyloarthritis, hidradenitis suppurativa | Psoriasis, PsA, AS, nr-axSpA, HS | Psoriasis; Atopic Dermatitis |
Overview Phase | APPROVED | APPROVED | APPROVED |
Overview Status | APPROVED | APPROVED | RECRUITING |
Overview Content status | Curated Core | Curated Core | Curated Core |
Overview Data Confidence | Editorial scope · Curated Core | Editorial scope · Curated Core | Editorial scope · Curated Core |
Overview Development Signal | Development Signal · Established | Development Signal · Established | Development Signal · Established |
Overview Approval status | FDA approved | FDA approved | Approved (flag incomplete) |
Positioning Key differentiator | IL-17F contributes independently to tissue inflammation, so blocking it as well raises the ceiling on complete skin clearance. | Novel approaches, including tolerogenic DC therapy and neuroimmune modulation, hold promise for refining treatment and addres | Novel approaches, including tolerogenic DC therapy and neuroimmune modulation, hold promise for refining treatment and addres |
Positioning Known limitation | Anti-drug antibodies and non-IL-17-driven inflammatory phenotypes. | bypassed its classic signal adaptor and directly interacted with the calcium-binding protein S100A9 | — |
Positioning Development positioning | 1L–2L biologic | — | — |
MoA Mechanism | Binds IL-17A and IL-17F, preventing engagement of the IL-17RA/RC complex and shutting down downstream keratinocyte and synovial inflammatory signaling more completely than IL-17A blockade alone. | Secukinumab binds IL-17A and prevents interaction with IL-17RA/RC receptor complex, inhibiting keratinocyte and synovial inflammation driven by Th17 pathway. | targets and signaling pathway |
MoA Biomarker | PASI/IGA response, hs-CRP in axial disease. | PASI, ASAS response, radiographic progression in SpA. | — |
Toxicology Species | Cynomolgus monkey | Mouse | — |
Toxicology Major finding | Oral candidiasis is the signature toxicity of IL-17F co-blockade and occurs in roughly 10–20% of patients. Upper respiratory infection is common; inflammatory bowel disease requires monitoring. | Nasopharyngitis, candidiasis (mucocutaneous), neutropenia; IBD caution in label. | — |
Toxicology CRS | N/A | N/A | — |
Clinical Safety signal | Oral candidiasis is the signature toxicity of IL-17F co-blockade and occurs in roughly 10–20% of patients. Upper respiratory infection is common; inflammatory bowel disease requires monitoring. | Nasopharyngitis, candidiasis (mucocutaneous), neutropenia; IBD caution in label. | — |
Clinical Program phase | APPROVED | APPROVED | APPROVED |
Clinical Trial activity | No active/completed counts | No active/completed counts | — |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 3개 · 임상 갱신 필요 3개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |||
|---|---|---|---|
Overview Program | Bimzelx (bimekizumab) | Cosentyx (secukinumab) | Ixekizumab |
Overview Company | UCB | Novartis | Eli Lilly and Company |
Overview Modality | ANTIBODY | ANTIBODY | ANTIBODY |
Overview Target | IL-17A / IL-17F | IL-17A | Psoriatic Arthritis |
Overview Indication | Plaque psoriasis, psoriatic arthritis, axial spondyloarthritis, hidradenitis suppurativa | Psoriasis, PsA, AS, nr-axSpA, HS | Psoriasis; Atopic Dermatitis |
Overview Phase | APPROVED | APPROVED | APPROVED |
Overview Status | APPROVED | APPROVED | RECRUITING |
Overview Content status | Curated Core | Curated Core | Curated Core |
Overview Data Confidence | Editorial scope · Curated Core | Editorial scope · Curated Core | Editorial scope · Curated Core |
Overview Development Signal | Development Signal · Established | Development Signal · Established | Development Signal · Established |
Overview Approval status | FDA approved | FDA approved | Approved (flag incomplete) |
Positioning Key differentiator | IL-17F contributes independently to tissue inflammation, so blocking it as well raises the ceiling on complete skin clearance. | Novel approaches, including tolerogenic DC therapy and neuroimmune modulation, hold promise for refining treatment and addres | Novel approaches, including tolerogenic DC therapy and neuroimmune modulation, hold promise for refining treatment and addres |
Positioning Known limitation | Anti-drug antibodies and non-IL-17-driven inflammatory phenotypes. | bypassed its classic signal adaptor and directly interacted with the calcium-binding protein S100A9 | — |
Positioning Development positioning | 1L–2L biologic | — | — |
MoA Mechanism | Binds IL-17A and IL-17F, preventing engagement of the IL-17RA/RC complex and shutting down downstream keratinocyte and synovial inflammatory signaling more completely than IL-17A blockade alone. | Secukinumab binds IL-17A and prevents interaction with IL-17RA/RC receptor complex, inhibiting keratinocyte and synovial inflammation driven by Th17 pathway. | targets and signaling pathway |
MoA Biomarker | PASI/IGA response, hs-CRP in axial disease. | PASI, ASAS response, radiographic progression in SpA. | — |
Toxicology Species | Cynomolgus monkey | Mouse | — |
Toxicology Major finding | Oral candidiasis is the signature toxicity of IL-17F co-blockade and occurs in roughly 10–20% of patients. Upper respiratory infection is common; inflammatory bowel disease requires monitoring. | Nasopharyngitis, candidiasis (mucocutaneous), neutropenia; IBD caution in label. | — |
Toxicology CRS | N/A | N/A | — |
Clinical Safety signal | Oral candidiasis is the signature toxicity of IL-17F co-blockade and occurs in roughly 10–20% of patients. Upper respiratory infection is common; inflammatory bowel disease requires monitoring. | Nasopharyngitis, candidiasis (mucocutaneous), neutropenia; IBD caution in label. | — |
Clinical Program phase | APPROVED | APPROVED | APPROVED |
Clinical Trial activity | No active/completed counts | No active/completed counts | — |
추천 비교
추천 비교